Windlas Biotech Limited (WINDLAS) — Announcement | 29 June 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Windlas Biotech Limited announced that ICRA reaffirmed its Long-Term Working Capital Facilities rating at A+ (Stable) and upgraded its Short-Term Working Capital Facilities rating from A+ to A1+. The upgrade reflects improved liquidity and creditworthiness, with the total rated facility amounting to ₹84.90 crores. This reaffirmation and upgrade signal stronger financial health and enhanced borrowing capacity, which may support future growth initiatives and investor confidence.

📄 View Original Announcement (PDF)

About Windlas Biotech Limited (WINDLAS)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,645.02 Cr P/E: 26.4

View full WINDLAS stock details →

📡 Get AI alerts when WINDLAS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track WINDLAS — Free

📊 More WINDLAS filings

See all WINDLAS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when WINDLAS files new disclosures

Track WINDLAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track WINDLAS — Free

Free account · 2 AI queries/day